Farrell Michael J. 4
4 · RESMED INC · Filed Jan 8, 2026
Insider Transaction Report
Form 4
RESMED INCRMD
Farrell Michael J.
DirectorChairman and CEO
Transactions
- Exercise/Conversion
ResMed Common Stock
2026-01-07$146.34/sh+4,991$730,383→ 471,214 total - Sale
ResMed Common Stock
2026-01-07$248.46/sh−4,991$1,240,065→ 466,223 total - Exercise/Conversion
ResMed Common Stock Options
2026-01-07−4,991→ 49,912 totalExercise: $146.34From: 2020-11-11Exp: 2026-11-21→ ResMed Common Stock (4,991 underlying)
Holdings
- 2,090(indirect: By Trust)
ResMed Common Stock
Footnotes (3)
- [F1]The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
- [F2]This transaction was executed in multiple trades at prices ranging from $246.801 - $249.969. The price reported above reflects the weighted average sale price.
- [F3]Represents date options first become exercisable. Options vest 1/3 per year.